Compare XTNT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 77.2M |
| IPO Year | 2009 | 2021 |
| Metric | XTNT | SERA |
|---|---|---|
| Price | $0.58 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 99.1K | 78.6K |
| Earning Date | 03-06-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $53,337,000.00 | $81,000.00 |
| Revenue This Year | $15.08 | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $19.34 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.34 | $1.37 |
| 52 Week High | $0.95 | $4.20 |
| Indicator | XTNT | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 28.39 |
| Support Level | $0.55 | $1.37 |
| Resistance Level | $0.68 | $2.00 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 26.21 | 11.25 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.